Dr. Shah on the Importance of CAR T-Cell Therapy for ALL

Bijal D. Shah, MD
Published: Wednesday, Nov 22, 2017



Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).

According to Shah, CAR T-cell therapy is the most promising therapy for patients with ALL. There are toxicities but the toxicities are manageable for the majority of patients. The risk of dying from toxicities is less than 5%.
 


Bijal D. Shah, MD, medical oncology, Moffit Cancer Center, discusses the importance of chimeric antigen receptor (CAR) T-cell therapy for patients with acute lymphoblastic leukemia (ALL).

According to Shah, CAR T-cell therapy is the most promising therapy for patients with ALL. There are toxicities but the toxicities are manageable for the majority of patients. The risk of dying from toxicities is less than 5%.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x